CAS No.51598-60-8,Cimetropium bromide Suppliers

Detail of "51598-60-8"

CAS Number:

51598-60-8

Name:

Cimetropium bromide

Molecular Structure:

Formula:

C₂₁H₂₈BrNO₄

Molecular Weight:

438.35

Synonyms:

3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide,[7(S)-(1a,2b,4b,5a,7b)]-;3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane,9-(cyclopropylmethyl)-7-[(2S)-3-hydroxy-1-oxo-2-phenylpropoxy]-9-methyl-, bromide,(1a,2b,4b,5a,7b)- (9CI);Alginor;

Reference

Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug: Discontinuous oral absorption of cimetropium bromide, a new antispasmodic drug. Imbimbo, B. P.; Daniotti, S.; Vidi, A.; Foschi, D.; Saporiti, F.; Ferrante, L. (Inst. De Angeli S.p.A., Milan, Italy). J. Pharm. Sci., 75(7), 680-4 (English) 1986. CODEN: JPMSAE. ISSN: 0022-3549. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The pharmacokinetic profiles of cimetropium bromide [51598-60-8], after either i.v. injection of 10 mg or oral ingestion of 200 mg, were detd. in healthy volunteers. After i.v. administration, the plasma levels and urinary excretion indicated that the drug is distributed and eliminated at a rapid rate (terminal half-life, 50 min) and the urinary excretion is not the exclusive route of elimination (46% of the administered dose). After oral administration, a low percentage of the drug is absorbed (1-4% of the administered dose); however, the amt. is sufficient for therapeutic effect. The absorption is discontinuous, with 2 distinct phases, and ends abruptly during the 2nd phase.

Relative potency of the atropine-like effects of a new parasympatholytic drug, scopolamine-N-(cyclopropyl methyl) bromide and those of hyoscine-N-butyl bromide: Relative potency of the atropine-like effects of a new parasympatholytic drug, scopolamine-N-(cyclopropyl methyl) bromide and those of hyoscine-N-butyl bromide. Litta-Modignani, R.; Mazzolari, M.; Barantani, E.; Bertoli, D.; Vibelli, C. (1st Med. Div., Osp. Gen. Prov., Treviglio, Italy). Curr. Med. Res. Opin., 5(4), 333-40 (English) 1978. CODEN: CMROCX. ISSN: 0300-7995. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacodynamics) A double-blind crossover trial with a 4-point bioassay was carried out in patients to study the relative potency of DA 3177 [scopolamine-N-(cyclopropylmethyl)bromide](I) [51598-60-8] administered at doses of 2.5 mg and 5 mg i.v., and hyoscine-N-Bu bromide [149-64-4] administered at doses of 10 mg and 20 mg i.v., in producing atropine-like effects. The effects on heart rate and near point of ocular accommodation were slightly less with I, whereas the effects on salivary secretion were a little greater with I than with hyoscine-N-Bu bromide. Thus, a study of the pharmacodynamic effects of parasympatholytic drugs is a relatively simple way of predicting which doses should be effective spasmolytically.

Detail of "51598-60-8"

Cimetropium bromide

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium Bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

CAS No.51598-60-8 Cimetropium bromide

Reference